Balanced news tone
News Sentiment
TENX sentiment intelligence
Tenax Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
77/100 classification confidence.
directly relevant articles
high-authority source matches
+13.5% over one week, +52.9% over four weeks, trend active, and materially above fair value.
Basic earnings per share (basic EPS) of Tenax Therapeutics, Inc. – TRADEGATE:YBO0
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Tenax Therapeutics: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 11:07
- Source
- Associated Press
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- GlobeNewswire
TENAX THERAPEUTICS ($TENX) Releases Q1 2026 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- Quiver Quantitative
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 11:00
- Source
- GlobeNewswire
Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- simplywall.st
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Tenax Therapeutics Names Thomas Staab as Chief Financial Officer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 12:50
- Source
- MT Newswires
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 11:00
- Source
- GlobeNewswire
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Tenax Therapeutics: A Binary Bet With Heavy Downside Likely (NASDAQ:TENX)
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Seeking Alpha
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 10 Mar 2026 07:00
- Source
- Investing News Network
Tenax Therapeutics Stock: A Speculative Buy (NASDAQ:TENX)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jan 2026 08:00
- Source
- Seeking Alpha
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Dec 2025 08:00
- Source
- Investing News Network
Tenax Therapeutics (TENX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 01:10
- Source
- Stock Titan
Tenax Therapeutics Announces Closing of $100 Million
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Aug 2024 07:00
- Source
- GlobeNewswire
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Aug 2024 07:00
- Source
- GlobeNewswire
Tenax Therapeutics Appoints Christopher T. Giordano as CEO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2021 07:00
- Source
- citybiz